Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Piramal Pharma Limited ( (IN:PPLPHARMA) ) has shared an update.
Piramal Pharma Limited has commenced commercial production of Sevoflurane at its facility in Digwal, Telangana, India. This expansion enhances the company’s manufacturing capabilities, allowing it to address opportunities in inhalation anesthesia markets beyond the USA, potentially strengthening its industry position and offering broader market access.
More about Piramal Pharma Limited
Piramal Pharma Limited operates in the pharmaceutical industry, focusing on the production of various pharmaceutical products. The company is involved in the manufacture and distribution of inhalation anesthesia products, with a market focus that includes both the USA and Rest of the World (ROW) markets.
YTD Price Performance: -13.04%
Average Trading Volume: 391,520
Current Market Cap: 297.6B INR
See more insights into PPLPHARMA stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money